Full name :
First name :
Mail :
Zip Code :
City :
Country :
Email :
Phone :
Fax :
Website :
Directory :
Title : Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging - |
Author(s) : Tawakol A , Singh P , Rudd JH , Soffer J , Cai G , Vucic E , Brannan SP , Tarka EA , Shaddinger BC , Sarov-Blat L , Matthews P , Subramanian S , Farkouh M , Fayad ZA |
Ref : J Am Coll Cardiol , 63 :86 , 2014 |
PubMedID: 23973698 |
Title : Peripheral artery disease, biomarkers, and darapladib - Berger_2011_Am.Heart.J_161_972 |
Author(s) : Berger JS , Ballantyne CM , Davidson MH , Johnson JL , Tarka EA , Lawrence D , Trivedi T , Zalewski A , Mohler ER, 3rd |
Ref : American Heart Journal , 161 :972 , 2011 |
Abstract : Berger_2011_Am.Heart.J_161_972 |
ESTHER : Berger_2011_Am.Heart.J_161_972 |
PubMedSearch : Berger_2011_Am.Heart.J_161_972 |
PubMedID: 21570531 |